A5028241549- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Venous Thromboembolism Diagnosis and Management
- Cancer Treatment and Pharmacology
- Hematopoietic Stem Cell Transplantation
- Colorectal Cancer Treatments and Studies
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Ovarian cancer diagnosis and treatment
- Advanced Breast Cancer Therapies
- Central Venous Catheters and Hemodialysis
- Cancer Genomics and Diagnostics
- T-cell and Retrovirus Studies
- Salivary Gland Tumors Diagnosis and Treatment
- Immune Cell Function and Interaction
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- Neutropenia and Cancer Infections
- Hepatocellular Carcinoma Treatment and Prognosis
- Medical Imaging Techniques and Applications
IRCCS Humanitas Research Hospital
2016-2025
Fondazione Humanitas per la Ricerca
2004-2024
Humanitas University
2013-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2020-2022
Istituto di Ematologia di Bologna
2000-2012
Centro di Riferimento Oncologico
2007-2009
University of Bologna
1996-2001
Istituto Oncologico Romagnolo
1996-2000
University of Bari Aldo Moro
2000
Sapienza University of Rome
1999
Nongastrointestinal locations represent about 30% to 40% of all low-grade mucosa-associated lymphoid tissue (MALT) lymphomas. We report a retrospective analysis 75 patients with nongastrointestinal MALT lymphoma, presenting their clinical, therapeutic, and follow-up data respect the initial location lymphoma.From January 1988 October 1997, untreated lymphoma were subjected treatments ranging from local radiotherapy interferon alfa administration chemotherapy. The lymphomas located in lung...
To evaluate the efficacy and toxicity of gemcitabine, a novel pyrimidine antimetabolite with low-toxicity profile activity in several solid tumors, patients relapsed or refractory cutaneous T-cell lymphomas.Between May 1997 February 1999, 44 previously treated mycosis fungoides (MF; n = 30) peripheral lymphoma unspecified (PTCLU) exclusive skin involvement (n 14) were enrolled onto two-institution, phase II trial gemcitabine. This drug was given on days 1, 8, 15 28-day schedule at dose 1,200...
Background and Objectives Response to pre-transplant salvage chemotherapy remains the most important prognostic factor for outcome in refractory or relapsed Hodgkin’s lymphoma. Results of a new induction regimen are reported terms response rates, toxicity, stem cell mobilization.Design Methods Ninety-one patients with lymphoma were treated prospectively consisting ifosfamide 2000 mg/m2 on days 1 4, gemcitabine 800 vinorelbine 20 day 1, prednisolone 100 mg 4 (IGEV).Results Forty-nine (53.8%)...
abstract Learning Objectives After completing this course, the reader will be able to: Use a modulation of chemotherapy according to modified geriatric assessment improve outcomes for elderly patients with diffuse large B-cell lymphoma an acceptable level toxicity.Offer best tailored treatment while minimizing dose-limiting toxicity. CME This article is available continuing medical education credit at CME.TheOncologist.com Chemotherapy associated toxicity in potentially curable malignancies,...
Abstract The standard treatment for young patients with untreated PTCLs is based on anthracycline containing-regimens followed by high-dose-chemotherapy and stem-cell-transplantation (HDT + SCT), but only 40% of them can be cured. Romidepsin, a histone-deacetylase inhibitor, showed promising activity in relapsed PTCLs; first line, Romidepsin was added CHOP. We designed study combining romidepsin CHOEP as induction before HDT auto-SCT (PTCL-NOS, AITL/THF, ALK-ALCL), aged 18–65 years. A phase...
The use of prophylactic low-dose oral warfarin in cancer patients with a central venous catheter (CVC) place has an established role the prevention thrombotic complications and is associated low hemorrhagic risk. Despite literature indicating adverse interaction between fluorouracil (FU), frequency this whether it occurs when minidose used unknown. We analyzed incidence alterations International Normalized Ratio (INR) bleeding given during treatment continuous-infusion FU-based...
PURPOSE: A first comparative trial of fludarabine (FLU) alone versus FLU plus idarubicin (FLU-ID) for indolent or mantle-cell lymphomas. PATIENTS AND METHODS: From September 1995 to July 1998, 199 patients aged 25 65 years (median, 54 years) with newly diagnosed stages II IV lymphomas (standard risk according the International Prognostic Index) were enrolled onto a multicenter, 1:1 randomized study. Of who able be assessed, 101 assigned group (six monthly cycles mg/m 2 /d on days 1 through...
Abstract Bromodomain and extraterminal proteins (BET) play key roles in regulation of gene expression, may a role cancer-cell proliferation, survival, oncogenic progression. CC-90010-ST-001 (NCT03220347) is an open-label phase I study trotabresib, oral BET inhibitor, heavily pretreated patients with advanced solid tumors relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Primary endpoints were the safety, tolerability, maximum tolerated dose, RP2D trotabresib. Secondary clinical...
Isolated central nervous system (CNS) relapse was evaluated in terms of incidence, risk factors, and outcome a consecutive cohort 175 patients with aggressive non-Hodgkin's lymphoma which no case lymphoblastic or Burkitt's encountered. All these had obtained complete remission first-line treatment none received prophylactic CNS at diagnosis. Nine (5.2%) developed isolated after median 8 months from involvement documented by cerebrospinal fluid (CSF) cytology 4 on the basis radiologic...
This retrospective study evaluated whether early 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) after two cycles of salvage chemotherapy (PET2) could predict survival high-dose (HDC). Twenty-four Hodgkin lymphoma (HL) patients were included. PET2 was negative in 58% and positive 42% patients. Ninety per cent (9/10) with relapsed HDC while all but one patient maintained a complete remission. The 2-year progression-free 93% vs. 10% for PET2, respectively (P <...
The International Extranodal Lymphoma Study Group coordinated a phase II trial to evaluate the activity and safety of everolimus in marginal zone lymphomas (MZLs). Thirty patients with relapsed/refractory MZLs received for six cycles or until dose-limiting toxicity progression. Median age was 71 years (range, 51-88 years). Twenty had extranodal, splenic, four nodal MZL. Twenty-four stage III-IV. number prior therapies two (range 1-5). Seventeen early treatment discontinuation, most cases due...
Summary Checkpoint inhibitors (CPIs) are routinely employed in relapsed/refractory classical Hodgkin lymphoma. Nonetheless, persistent long‐term responses uncommon, and one‐third of patients refractory. Several reports have suggested that treatment with CPIs may re‐sensitize to chemotherapy, however there is no consensus on the optimal chemotherapy regimen subsequent consolidation strategy. In this retrospective study we analysed response rechallenge after CPI failure. Furthermore,...
PURPOSE In the last few years, search for new biologic markers in high-grade non-Hodgkin's lymphomas has provided important results. particular, soluble CD30 (sCD30) levels were elevated most patients with Hodgkin's disease (HD) and anaplastic large-cell lymphoma (ALCL). PATIENTS AND METHODS From September 1988 to October 1993, treatment was completed 70 previously untreated ALCL, of whom 38 had common type (ALCL-CT) 32 Hodgkin's-like subtype (ALCL-HL). Serum sCD30 measured at time diagnosis...